2024-02-12 12:13:32 ET
More on ATAI, COMPASS Pathways, etc.
- Compass Pathways: Psilocybin Developer A Potentially Intriguing, Contrarian Play
- Mind Medicine: Positive MM-120 Data Leads To Other 2024 Catalysts
- De-Risking Psychedelics: Compass Pathways, Cybin And Atai
- Cybin reports Japan grant of additional patents for anxiety disorder treatment
- Compass Pathways and Greenbrook TMS enter into three-year research collaboration agreement
Read the full article on Seeking Alpha
For further details see:
Psychedelic stocks gain after FDA priority review for MDMA therapy